Thanks to the unwavering support of people like you, we’ve raised $10M towards our five-year, $50-million-dollar Meet Hope Head On campaign goal.
Reaching this milestone gets us closer to our three campaign goals:
- To triple our research investment.
- To double patients served.
- To double federal funding of brain tumor research.
Last year, the ABTA awarded over $1.47M in research grants, the highest amount in over a decade, and yet, many promising research projects from talented researchers went unfunded.
Building on this momentum, we’re eager to share with you just how the ABTA is growing its investment in research.
What we'll do:
- Support more early-career researchers to pursue high-risk, high-impact research through an increased number of research grants and a larger investment. We aim to exceed the $1.47M invested in 2024.
- Invest in large-scale research projects through collaboration via the Brain Tumor Funders Collaborative. Our focus: research projects that address a need in the field relevant to both adult and pediatric brain tumors, for funding in 2025. Keep reading MindMatters for updates on this exciting collaboration! Learn more.
- Grow and support our Alumni Research Network through the addition of new members and our 13th Annual Meeting for researchers to network and accelerate scientific exchange. Learn more.
- Accept grant applications from our flexible research fund to support innovative research to address understudied and underfunded “gap areas."
- Fortify our commitment to improving outcomes for metastatic brain tumor patients by working with our Metastatic Brain Tumor Collaborative partners to develop a new grant opportunity in 2024 specific to brain mets research, for funding in 2025.
Thanks again for your unwavering support of Meet Hope Head On, a five-year, $50-million campaign that will give the ABTA the resources it needs to triple our research investment, double the patients we serve, and double federal funding for brain tumor research. You can learn more about the campaign at meethopeheadon.org.
Did you know?
More than 80% of grade 2 glioma patients have cancers with IDH mutations that drive glioma formation. The IDH mutations were discovered in 2008, through your donations, by an ABTA-supported researcher. These efforts led to the first late-stage study to target those mutations in brain cancer.
Jessie Schlacks
Jessie is Managing Editor of the bi-monthly e-newsletter MindMatters. Submit story ideas or questions to jschlacks@abta.org.
